View all recent publications

Joseph Mikhael

MD

Mayo Clinic

Dr. Mikhael’s predominant research interest is in multiple myeloma and its related conditions: Waldenstrom’s macroglobulinemia and amyloidosis. He also does research in medical education, benign hematology and pharmacoeconomics:

Multiple myeloma, Waldenstrom’s and amyloidosis: He is the principal investigator of multiple clinical trials in both newly diagnosed and relapsed disease. He is also interested in the field of quality-of-life in multiple myeloma patients.
Medical education: Dr Mikhael is interested in various innovative methods of medical education.
Benign hematology: He is involved in research in agents for thrombosis. He also is involved in ITP research.
Pharmacoeconomics: He develops models to account for the cost of cancer care and validates therapies based upon their cost-effectiveness.

Social media – a useful tool for hematological research

Venetoclax as a potential treatment for MM with t(11;14)

Isatuximab and pomalidomide for the treatment of MM

Marginalized and high-risk multiple myeloma patients: how to address this issue

Developments in multiple myeloma – immunotherapy and personalized medicine

The potential of tweet chats

The benefits of video on social media

Why research institutes should use social media

The use of social media to reach out to patients and help improve clinical trials

Multiple myeloma highlights from ASCO 2016: monoclonal antibodies and oral proteasome inhibitors

Embracing the use of social media at medical congresses

Where do new drugs fit into the treatment landscape of multiple myeloma?

The Phase II clinical trial of ixazumib, the first oral proteasome inhibitor in MM

Social Media for the Hematologist by Dr Joseph Mikhael

Overview of a Phase II clinical trial of isatuximab

Results of the phase 2 trial of daratumumab in multiple myeloma

1
2
Next